-
Vorolanib Tablets Approved for Marketing by China NMPA
2023-06-08
Recently, the Category 1 innovative drug Vorolanib Tablets (Chinese trade name: 伏美纳) of Betta Pharmaceuticals Co., Ltd is approved by China NMPA.
-
Innovative TCM Shenyu Ningshen Tablet Approved for Marketing by China NMPA
2023-06-08
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenyu Ningshen Tablets of Guangdong Siji Pharmaceutical Co., Ltd was approved for marketing by China NMPA.
-
Computer-aided Detection Software for Electronic Endoscope for Colon Polyps Approved for Marketing
2023-06-01
Recently, the innovative product computer-aided detection software for electronic endoscope for colon polyps of Tencent Healthcare (Shenzhen) Co., Ltd. is approved by China NMPA.
-
Coronary Interventional Surgical Control System with One-off Accessories Approved for Marketing
2023-06-01
Recently, the innovative product Coronary Interventional Surgical Control System with one-off accessories of Corindus Inc. is approved by China NMPA.
-
Shenge Bushen Capsule Approved for Marketing by China NMPA
2022-12-29
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenge Bushen Capsule of Xinjiang Huachun Biological Pharmaceutical Co., Ltd was approved for marketing by China NMPA.
-
Qijiao Tiaojing Granule Approved for Marketing by China NMPA
2022-12-28
Recently, the new traditional Chinese medicine (TCM) compound preparation Qijiao Tiaojing Granule of Hunan Anbang Pharmaceutical Co., Ltd. was approved for marketing by China NMPA.
